Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BeyondMD vs Mevo Health

BeyondMD
Graded #176

Higher grade

vs+6.599999999999994
Mevo Health
Graded #326

Lower grade

The verdict

BeyondMD takes it — 66.8/100 to 60.2/100.

BeyondMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth clinic offering competitively priced compounded semaglutide and tirzepatide.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBeyondMD +20
76
56
Dose & formulationMevo Health +19
64
83
Clinical oversightBeyondMD +7
74
67
Labs & monitoringBeyondMD +1
53
52
FulfillmentBeyondMD +8
65
57
Contract termsBeyondMD +35
55
20
BeyondMD · left barMevo Health · right bar

The numbers

MetricBeyondMDMevo Health
WeighScore66.8/10060.2/100
GradeCC
Scorecard rank#176#326
Semaglutide$139/mo (starting dose, compounded)$199/mo (all doses, compounded)
Tirzepatide$209/mo (starting dose, compounded)$259/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
BeyondMD

Graded #176 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard